Posted by Michael Wonder on 02 Apr 2026
Pasithea Therapeutics announces grant of fast track designation by FDA to PAS-004 for treatment of neurofibromatosis type 1 associated plexiform neurofibromas causing significant morbidity
1 April 2026 - Pasithea Therapeutics today announced that the US FDA has granted fast track designation to PAS-004 for the treatment of neurofibromatosis type 1 associated plexiform neurofibromas causing significant morbidity.
The Company is currently conducting a Phase 1/1b multi-centre, open-label, dose escalation trial of PAS-004 in adult participants with symptomatic, inoperable, incompletely resected, or recurrent neurofibromatosis type 1 associated plexiform neurofibromas.
